Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: A review of a special problem

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 7, 2006, Pages 297-302

  Klotz, Ulrich ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Clinical outcome; CYP2C19 polymorphism; Pharmacodynamics; Pharmacokinetics; Proton pump inhibitors

Indexed keywords

AMOXICILLIN; CHROMOGRANIN A; CLARITHROMYCIN; CYANOCOBALAMIN; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; ESOMEPRAZOLE; GASTRIN; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PEPSINOGEN; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ALLELE; AREA UNDER THE CURVE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; ERADICATION THERAPY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MULTIPLE DRUG DOSE; PEPTIC ULCER; PHENOTYPE; REVIEW; STOMACH ACID SECRETION; STOMACH PH; TREATMENT OUTCOME; ULCER HEALING; WILD TYPE;

EID: 33745914612     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44297     Document Type: Review

References (22)

1. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001; 40: 411-426.
2. Dickson EJ, Stuart RC. Genetics of response to proton pump inhibitor therapy. Clinical implications. Am J Pharmacogenomics. 2003; 3: 303-315.
3. Furuta T, Shirai N, Watanabe F, Honda S, Takeuchi K, Iida I et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther. 2002; 72: 453-460.
4. Gaedigk A. Interethnic differences of drug metabolizing enzymes. Int J Clin Pharmacol Ther. 2000; 38: 61-68.
5. Hellström PM, Vitols S. The choice of proton pump inhibitor: does it matter? Basic Clin Pharmacol Toxicol. 2004; 94: 106-111.
6. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of protein pump inhibitors - emphasis on rabeprazole. Aliment Pharmacol Ther. 1999; 13 (Suppl 3): 27-36.
7. Junghard O, Hassan-Alin M, Hasselgren G. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentrations of esomeprazole on intragastric pH. Eur J Clin Pharmacol. 2002; 58: 453-458.
8. Kawamura M, Ohara S, Koike T, Iijima K, Suzuki J, Kayaba S et al. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther. 2003; 17: 965-973.
9. Kirchheiner J, Fuhr U, Brockmöller J. Pharmacogenetics-based therapeutic recommendations - ready for clinical practice? Nature Rev/ Drug Discovery. 2005; 4: 639-647.
10. Klok RM, Postma MJ, van Hout BA, Brouwers JRBJ. Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther. 2003; 17: 1237-1245.
11. Klotz U. The changing target in the treatment of peptic ulcer: from pH to Hp. In: Gupta SK (ed): Pharmacology and therapeutics in the new millenium. New Delhi, India: Narosa Publ House; 2001. pp 587-598.
12. Klotz U, Schwab M, Treiber M. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol. 2004; 95: 2-8.
13. Lind T, Cederberg G, Ekenved U, Haglund U, Olbe L. Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin-stimulated acid secretion in man. Gut. 1983; 24: 270-276.
14. Phillips KA, van Bebber SL. Measuring the value of pharmacogenomics. Nature Rev/Drug Discovery. 2005; 4: 500-509.
15. Raghunath AS, O'Morain CD, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther. 2005; 22 (Suppl 1): 55-63.
16. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors. What the practising physician needs to know. Drugs. 2003; 63: 2739-2754.
17. 12 in patients on long-term omeprazole treatment. Aliment Pharmacol Ther. 1999; 13: 453-458.
18. Sagar M, Tybring G, Dahl ML, Bertilsson L, Seensalu R. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. Gastroenterology. 2000; 119: 670-676.
19. Schwab M, Schaeffeler E, Klotz U, Treiber G. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther. 2004; 76: 201-209.
20. Schwab M, Klotz U, Hofmann U, Schaeffeler E, Leodolter A, Malfertheiner P, Treiber G. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. Clin Pharmacol Ther. 2005; 78: 627-634.
21. Steinijans VW, Huber R, Hartmann M, Zech K, Bliesath H, Wurst W, Radtke HW. Lack of pantoprazole drug interactions in man: an updated review. Int J Clin Pharmacol Ther. 1996; 34: 243-262.
22. Vergara M, Vallve M, Gisbert JP, Calvet X. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003; 18: 647-654.